dFdC, either alone or in combination with paclitaxel albumin-bound particles (Abraxane), is used as a frontline regimen for pancreatic cancer chemotherapy; however, its limited benefits on treatment and survival outcomes are of significant concern. Here, ALB is linked to pancreatic neoplasm.